Aprocitentan

Generic Name
Aprocitentan
Brand Names
Jeraygo
Drug Type
Small Molecule
Chemical Formula
C16H14Br2N6O4S
CAS Number
1103522-45-7
Unique Ingredient Identifier
MZI81HV01P
Background

Aprocitentan is under investigation in clinical trial NCT03541174 (A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

Phase 1
Completed
Conditions
Hepatic Impairment
Healthy Subjects
Interventions
Drug: Aprocitentan
First Posted Date
2020-02-05
Last Posted Date
2022-11-23
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
17
Registration Number
NCT04252495
Locations
🇩🇪

CRS Clinical Research Services Kiel GmbH, Kiel, Germany

🇵🇱

Biokinetica S.A., Jozefow, Poland

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Rosuvastatin
Drug: Aprocitentan
First Posted Date
2017-08-10
Last Posted Date
2022-11-29
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
20
Registration Number
NCT03245229
Locations
🇨🇿

Cepha s.r.o, Plzen, Czechia

A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease

Phase 1
Completed
Conditions
Healthy Subjects
Severe Renal Impairment
Interventions
Drug: ACT-132577
First Posted Date
2017-05-24
Last Posted Date
2022-11-23
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
16
Registration Number
NCT03165071
Locations
🇨🇿

CEPHA, Plzen, Czechia

A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Midalozam
Drug: Aprocitentan
First Posted Date
2016-07-22
Last Posted Date
2022-11-29
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
20
Registration Number
NCT02841761
Locations
🇺🇸

Investigator Site, Newark, New Jersey, United States

Clinical Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Other: Placebo
Drug: Aprocitentan
First Posted Date
2016-03-15
Last Posted Date
2022-11-29
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
24
Registration Number
NCT02708004
Locations
🇨🇭

Investigator Site Lausanne, Lausanne, Switzerland

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy